Mustang Bio (NASDAQ:MBIO – Get Free Report) released its quarterly earnings data on Thursday. The company reported ($0.14) earnings per share for the quarter, FiscalAI reports.
Mustang Bio Price Performance
MBIO stock traded down $0.00 during trading hours on Friday, reaching $0.39. 8,480 shares of the stock were exchanged, compared to its average volume of 101,359. The firm’s 50-day moving average is $0.46 and its 200-day moving average is $0.68. The company has a market cap of $2.98 million, a price-to-earnings ratio of -0.87 and a beta of 2.19. Mustang Bio has a 12 month low of $0.35 and a 12 month high of $1.43.
Institutional Trading of Mustang Bio
A hedge fund recently bought a new stake in Mustang Bio stock. BlackRock Inc. bought a new stake in Mustang Bio, Inc. (NASDAQ:MBIO – Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 84,745 shares of the company’s stock, valued at approximately $59,000. BlackRock Inc. owned about 1.12% of Mustang Bio as of its most recent filing with the SEC. 9.95% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Mustang Bio in a report on Thursday, October 15th. One investment analyst has rated the stock with a Sell rating. According to data from MarketBeat, Mustang Bio presently has an average rating of “Sell”.
Check Out Our Latest Report on Mustang Bio
About Mustang Bio
Mustang Bio, Inc is a clinical-stage biopharmaceutical company focused on developing cell and gene therapies for serious diseases, including cancer and rare genetic disorders. The company’s work centers on engineered immune-cell therapies designed to recognize and attack cancer cells, as well as gene therapies intended to address underlying disease causes.
Mustang’s development programs have included CAR T-cell therapies for hematologic malignancies and solid tumors. Its pipeline has featured MB-106, an investigational CD20-targeted CAR T-cell therapy for certain B-cell cancers, and programs targeting glioblastoma and other difficult-to-treat cancers.
Featured Stories
- Five stocks we like better than Mustang Bio
- Powering Up: Freeport-McMoRan’s $4.5B Copper Expansion
- 3 Dividend ETFs Offer Different Ways to Navigate the Post-Election Sell-Off
- Riot’s $28B Lease Shows Why Location and Contracts Matter in AI
- These 3 Underperforming Stocks Are Seeing Notable CEO Insider Trades
Receive News & Ratings for Mustang Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mustang Bio and related companies with MarketBeat.com's FREE daily email newsletter.
